Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00476541 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (NCT00476541)

Trial Description
The overall objective is to improve the cure rate of children with newly diagnosed acute myeloid leukemia (AML) who undergo risk-adapted therapy.

Stem cell transplantation (SCT) is reserved to high-risk patients defined by cytogenetics and response to chemotherapy. The efficacy and toxicity of the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) will be evaluated.

This trial is sponsored by University of Aarhus. [1]

Study Data

  • Condition: Acute Myeloid Leukemia (AML)
  • Interventions:
  • Phase: III
  • Estimated Enrollment: 250
  • Start: January 2004
  • Estimated Completion: January 2014
  • Last verified: March 2012

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 22, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar